Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).The analyst commented, "Despite solid execution ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE